- Home
- TNET vs SLS Comparison
TNET vs SLS Comparison
Compare TNET & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNET | SLS |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2000 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TNET | SLS |
|---|---|---|
| Price | $68.92 | $13.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $65.80 | $10.00 |
| AVG Volume (30 Days) | 314.9K | ★ 6.7M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 3.05 | N/A |
| Revenue | ★ $5,010,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.30 | $110.98 |
| P/E Ratio | $22.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.67 | $1.39 |
| 52 Week High | $73.08 | $15.88 |
Technical Indicators
Market Signals| Indicator | TNET | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 53.11 |
| Support Level | $56.53 | $11.43 |
| Resistance Level | $72.54 | $15.77 |
| Average True Range (ATR) | 2.42 | 1.24 |
| MACD | -0.63 | -0.06 |
| Stochastic Oscillator | 60.68 | 36.45 |
Price Performance
Historical ComparisonAbout TNET TriNet Group Inc.
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.